Showing results (3161-3170 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|August 7, 2023
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fateTianxiao Xu, Jie Dai, Lirui Tang, et al.Cancer Immunology, Immunotherapy : CII|August 4, 2023
Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database studyChikako Iwai, Taisuke Jo, Takaaki Konishi, et al.Cancer Immunology, Immunotherapy : CII|August 1, 2023
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapySteven H Sun, Colin D Angell, Himanshu Savardekar, et al.Cancer Immunology, Immunotherapy : CII|August 23, 2023
Th1 cytokines in pediatric acute lymphoblastic leukemiaSarah Schober, Jennifer M Rottenberger, Johannes Hilz, et al.Cancer Immunology, Immunotherapy : CII|September 5, 2023
PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancerKento Kawasaki, Kazuhiro Noma, Takuya Kato, et al.Cancer Immunology, Immunotherapy : CII|August 21, 2023
A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancerAyse Ece Gulen, Rakesh Rudraboina, Mohammad Tarique, et al.Cancer Immunology, Immunotherapy : CII|August 30, 2023
Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancerKoji Teramoto, Tomoyuki Igarashi, Yoko Kataoka, et al.Cancer Immunology, Immunotherapy : CII|September 28, 2023
An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy responseDidem Naz Dioken, Ibrahim Ozgul, Irem Yilmazbilek, et al.Cancer Immunology, Immunotherapy : CII|June 25, 2023
The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicityCarlo Girone, Federica Calati, Irene Lo Cigno, et al.Cancer Immunology, Immunotherapy : CII|June 13, 2023
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agentsClaire Battin, Annika De Sousa Linhares, Judith Leitner, et al.Pageof 652